NEWS AND EVENTS

19
Mar
Velicept Therapeutics Initiates First of Two Phase 2b Dose-Ranging Studies of Solabegron in Patients with Overactive Bladder (OAB); Finalizes Novel, Once Daily Formulation; and Receives U.S. Patent Covering OAB

-First study has begun enrolling patients to evaluate twice-daily formulation- -Second study to begin in the second quarter to assess once-daily dosing with the novel QD formulation- -Issuance of U.S. Patent No. 9,907,767 further expands Velicept’s patent portfolio covering Solabegron- MALVERN, PA – March 19, 2018 – Velicept Therapeutics, a privately-held specialty pharmaceutical company dedicated […]

Posted in: Uncategorized,
27
Oct
Velicept Therapeutics, Inc. Names Clarence Young, M.D., Chief Medical Officer

Velicept Therapeutics, Inc. announced today Clarence Young, M.D. has joined its leadership team as the company’s Chief Medical Officer.

Posted in: Uncategorized,
05
Oct
VELICEPT THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION OF NOVEL, ONCE-DAILY FORMULATION OF SOLABEGRON FOR THE TREATMENT OF OVERACTIVE BLADDER

Malvern, PA, October 5, 2016 (BUSINESS WIRE) – Velicept Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application to initiate a Phase I pharmacokinetic study for a once-daily formulation for solabegron.

Posted in: Uncategorized,